Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Muhammad Waqar ◽  
Braira Wahid ◽  
Muhammad Idrees ◽  
Muhammad Ali ◽  
Zobaria Rehman

Abstract The emergence of the pandemic in 2020 is a huge threat to global public health. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in China in December 2019 and later spread to almost all parts of the world in four months and declared as a pandemic in March 2020. SARS-CoV-2 has infected 15.8 million people worldwide while 641,000 died of it. This study aims to report the seroprevalence of SARS-CoV-2 in Pakistan. Of total of 635 samples of symptomatic individuals processed at Genome Center for Molecular Based Diagnostics and Research Pakistan, 313 (49.3%) were found SARS-CoV-2 seropositive. The study also confirmed more seroprevalence in elderly patients (>80 years) and children less than 13 years.

2021 ◽  
pp. 19-23
Author(s):  
Donizete Tavares Da Silva ◽  
Priscila De Sousa Barros Lima ◽  
Renato Sampaio Mello Neto ◽  
Gustavo Magalhães Valente ◽  
Débora Dias Cabral ◽  
...  

In March 2020, the World Health Organization (1) declared COVID-19 as a pandemic and a threat to global public health (2). The virus mainly affects the lungs and can cause acute respiratory distress syndrome (ARDS). In addition, coronavirus 2 severe acute respiratory syndrome (SARSCOV2) also has devastating effects on other important organs, including the circulatory system, brain, gastrointestinal tract, kidneys and liver


2020 ◽  
Vol 11 (7) ◽  
Author(s):  
Xing Li ◽  
Ying Wang ◽  
Patrizia Agostinis ◽  
Arnold Rabson ◽  
Gerry Melino ◽  
...  

Abstract The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.


2021 ◽  
Vol 15 (03) ◽  
pp. 366-369
Author(s):  
Rooh Ullah ◽  
Muhammad Suleman Rana ◽  
Mehmood Qadir ◽  
Muhammad Usman ◽  
Niaz Ahmed

Pandemic of novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in China is now become global public health crisis. At present 87.64% of the world is infected by this deadly illness. The risk from this epidemic depends on the nature of the virus, including how well it transmits from person to person, and the complications resulting from this current illness. The novel coronavirus has killed thousands of people in China and other countries as well; its rate of mortality is increasing day by day. There is an urgent need to control the virus by developing vaccine or any other antiviral drugs to save the world from this deadly viral infection.


2020 ◽  
Vol 1 (1) ◽  
pp. 176-182
Author(s):  
Bijay Singh

The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no approved vaccines or medications exist to prevent infection by SARS-CoV-2. In this emergency, more than 100 vaccines formulated using conventional approaches are being explored against SARS-CoV-2 across the world. The vaccines formulated using nanotechnology are also on the race of clinical trials. The aim of this article is to provide an insight into the ways of vaccine production by conventional and nanotechnology platforms and expand the understanding on the possibilities and limitations of these approaches for vaccine developments.


2020 ◽  
Vol 8 (T1) ◽  
pp. 122-125
Author(s):  
Idris Nasir Abdullahi ◽  
Anthony Uchenna Emeribe ◽  
Peter Elisha Ghamba ◽  
Musa Sani

For over 6 months of its emergence, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic, has resulted to unprecedented global health challenge and economic uncertainties. The pandemic swiftly disseminated to almost all the countries and territories of the world. The index case in Nigeria was imported by an Italian citizen on February 27, 2020. Typical of a novel respiratory tract viral infection, the spread of SARS-CoV-2 in Nigeria was slow in the first few days. However, as at 8:00 AM GMT+1, July 1, 2020, there were 25694 confirmed COVID-19 cases. With the continuous daily rise in the incidence of SARS-CoV-2 infection, enhanced surveillance programs were immediately activated and implemented in all parts of Nigeria. Even though an inadequate number of persons have been tested so far, the government of Nigeria has been activating public health laboratories to scale up its testing capacity. Due to the impact of partial lockdown and curfew in most states of Nigeria, the government has been able to provide some form of palliatives to vulnerable populations. This study aims to review and present the various public health and socioeconomic responses and challenges of the COVID19 pandemic in Nigeria. This reflects the efforts and successful steps taken to minimize the spread of COVID-19 in Nigeria.  


2020 ◽  
Vol 18 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Shishir Paudel ◽  
Ganesh Dangal ◽  
Anisha Chalise ◽  
Tulsi Ram Bhandari ◽  
Ojash Dangal

Coronavirus disease 2019 (COVID-19) is a newly emerged disease that has become a global public health concern as it rapidly spread around the world. The etiologic agent responsible for this disease has been named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses as it shows similar genomic features to that of SARS-CoV which caused a pandemic in 2002. This disease first appeared in Hubei province of China and it follows human-to-human transmission but the path this virus took to set up human infection remains a mystery. By 17 April 2020, globally there have been 2,074,529 confirmed cases with 139,378 deaths because of COVID-19. SARS-CoV-2 shows several similarities with SARS?CoV, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) with its clinical presentations. This can vary from asymptomatic infection to severe disease and mortality. Real-time reverse-transcription polymerase chain reaction (rRT-PCR) screening is considered as the standard laboratory test for the diagnosis of COVID-19. There is no proven antiviral agent against SARS-CoV-2 so the treatment for COVID-19 is symptomatic, aiming for the management of the symptoms and prevention of the complications. The outbreak of COVID-19 has led to the implementation of extraordinary public health measures throughout the world. Numerous antiviral compounds used to treat other infections are being clinically researched to find possible treatment. Similarly, the traditional public health outbreak response strategy of isolation, quarantine, social distancing and community containment has been implemented in multiple countries and has played an important role in the prevention of new outbreaks. This review aims to enhance our understanding of COVID 19.Keywords: Coronavirus disease 2019; COVID-19; SARS-CoV-2; novel coronavirus 2019; severe acute respiratory syndrome-2


2021 ◽  
Vol 12 ◽  
Author(s):  
Yandi Zhang ◽  
Jo-Lewis Banga Ndzouboukou ◽  
Mengze Gan ◽  
Xiaosong Lin ◽  
Xionglin Fan

Coronavirus disease 2019 (COVID-19) pandemic is a serious threat to global public health and social and economic development. Various vaccine platforms have been developed rapidly and unprecedentedly, and at least 16 vaccines receive emergency use authorization (EUA). However, the causative pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has continued to evolve and mutate, emerging lots of viral variants. Several variants have successfully become the predominant strains and spread all over the world because of their ability to evade the pre-existing immunity obtained after previous infections with prototype strain or immunizations. Here, we summarized the prevalence and biological structure of these variants and the efficacy of currently used vaccines against the SARS-CoV-2 variants to provide guidance on how to design vaccines more rationally against the variants.


2014 ◽  
Vol 27 (3) ◽  
pp. 511-529 ◽  
Author(s):  
Sudeepa Abeysinghe

ArgumentScientific uncertainty is fundamental to the management of contemporary global risks. In 2009, the World Health Organization (WHO) declared the start of the H1N1 Influenza Pandemic. This declaration signified the risk posed by the spread of the H1N1 virus, and in turn precipitated a range of actions by global public health actors. This article analyzes the WHO's public representation of risk and examines the centrality of scientific uncertainty in the case of H1N1. It argues that the WHO's risk narrative reflected the context of scientific uncertainty in which it was working. The WHO argued that it was attempting to remain faithful to the scientific evidence, and the uncertain nature of the threat. However, as a result, the WHO's public risk narrative was neither consistent nor socially robust, leading to the eventual contestation of the WHO's position by other global public health actors, most notably the Council of Europe. This illustrates both the significance of scientific uncertainty in the investigation of risk, and the difficulty for risk managing institutions in effectively acting in the face of this uncertainty.


2020 ◽  

In the past 100 years, the world has faced four distinctly different pandemics: the Spanish flu of 1918-1919, the SARS pandemic of 2003, the H1N1 or “swine flu” pandemic of 2012, and the ongoing COVID-19 pandemic. Each public health crisis exposed specific systemic shortfalls and provided public health lessons for future events. The Spanish flu revealed a nursing shortage and led to a great appreciation of nursing as a profession. SARS showed the importance of having frontline clinicians be able to work with regulators and those producing guidelines. H1N1 raised questions about the nature of a global organization such as the World Health Organization in terms of the benefits and potential disadvantages of leading the fight against a long-term global public health threat. In the era of COVID-19, it seems apparent that we are learning about both the blessing and curse of social media.


Author(s):  
Hassan Imam

In January 2020, the World Health Organization declared a public health emergency and announced a new coronavirus disease (COVID-19), which would later go on to be declared as a pandemic, changing the global sphere and placing the economies of almost all countries under heavy stress. The airline industry, that had just begun recovering after facing crises one after another in the last two decades, from early 2000 due to 9/11, to the global financial crisis later, is now oce again facing an enormous challenge of closed borders and greater lockdowns due to the pandemic. Borders are closed, with very few planes are in the air, while the rest are grounded. The purpose of this paper is to give a conceptual understanding of the current pandemic situation and its consequences on the airline industry. The paper takes a unique perspective of human resource management (HRM) that is rarely used in the airline industry.


Sign in / Sign up

Export Citation Format

Share Document